Clinical Trials at Retina-Vitreous Associates Medical Group
The physicians at Retina-Vitreous Associates Medical Group are involved in clinical research potentially leading to the development of new diagnostic and therapeutic modalities for retinal disease. Retina-Vitreous Associates Medical Group participates in most clinical trials assessing new therapies for macular degeneration and diabetic retinopathy amongst other retinal diseases. Currently enrolling clinical trials center on patients with diagnoses of:
- Wet AMD, treatment naïve patients and patients who have had AMD treatments
- Diabetic Retinopathy
- Central Retinal Vein Occlusion
- Retinitis Pigmentosa
- Geographic Atrophy
- Polypoidal Choroidal Vasculopathy
- Rhegmatogenous Macula-Off Retinal Detachment
Our clinical trials department can be contacted directly at
(310) 289-2478 [option 3].
Ongoing clinical trials (closed to enrollment):
(Further information is available by clicking on the name of the clinical trial. Scroll down to view the complete listing of currently enrolling clinical trials. However, please note that not all clinical trials have a corresponding website.)
Wet Age-Related Macular Degeneration - (treatment Naïve)
- Regeneron Pharmaceuticals VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration
- National Eye Institute Comparison of AMD Treatments Trials (CATT): Lucentis - Avastin Trial. A multicenter clinical trial to compare the relative safety and effectiveness of two drugs currently used to treat advanced age-related macular degeneration (AMD).
- NeoVista (CABERNET): A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
- Ophthotech Corporation OPH2000: A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis® 0.5 mg/Eye, Or With One Induction Dose Of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
- Oregon Health and Science University: The Effect of Genotype and Environmental Risk Factors on Treatment Response to Intravitreal Lucentis for Neovascular AMD (wet AMD).
Wet Age-Related Macular Degeneration - (previously treated)
- GlaxoSmithKline MD7108240: A Double-Masked, Randomized, Parallel-Group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-Related Macular Degeneration
- Jerini Ophthalmic JO642701: A Phase 1 Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients With Neovascular AMD
- Potentia Pharmaceuticals, Inc. POT-CP1006: Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Quark Pharmaceuticals QRK.003: A Phase 1 Open-Label, Dose Escalation Trial of REDD14NP Delivered by a Single Intravitreal Injection to Patients With Choroidal Neovascularization (CNV) Secondary to Exudative Age-Related Macular Degeneration ("Wet AMD")
- CoMentis ATG003-203: A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab)
Diabetic Macular Edema
- iCo Therapeutics Inc. 2006-007-01-DME: A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects with Diffuse Diabetic Macular Edema
- Genentech FVF4168g: A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus
- Allergan 206207-012: (Purpose - This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema.)
- National Eye Institute (NEI) Jaeb Center for Health Research (DRCR.net) NEI-133: Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema
- National Eye Institute (NEI) Jaeb Center for Health Research (DRCR.net) NEI-134: Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- Vitreoretinal Technologies, Inc. PVD-301: A Phase 3 Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects
Retinal Vein Occlusion
- Genentech (CRUISE) FVF4166g: A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion
Geographic Atrophy
- Alcon Research (GAP) C-06-30: (Purpose - The objective of the 18-month trial is to evaluate the natural history of geographic atrophy by assessing the rate of progression of the geographic atrophic lesion over time.)
- Allergan 190342-032D: Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD
Retinitis Pigmentosa
- Allergan 190342-028D: (Purpose - This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis Pigmentosa.)